Skip to main content
Journal cover image

Peptide-derivatized shell-cross-linked nanoparticles. 2. Biocompatibility evaluation.

Publication ,  Journal Article
Becker, ML; Bailey, LO; Wooley, KL
Published in: Bioconjugate chemistry
July 2004

The conjugation of the protein transduction domain (PTD) from the HIV-1 Tat protein to shell cross-linked (SCK) nanoparticles is a method to facilitate cell surface binding and transduction. In the previous report, the preparation, derivatization, and characterization of peptide-functionalized SCK nanoparticles were reported in detail. Following assembly, the constructs were evaluated in vitro and in vivo to obtain a preliminary biocompatibility assessment. The effects of SCK exposure on cell viability were evaluated using a metabolic 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) and a fluorescent apoptosis assay. Furthermore, stages of apoptosis were quantified by flow cytometry. Although higher levels of peptide functionalization resulted in decreased metabolic function as measured by MTT assay, significant apoptosis was not observed below 500 mg/L for all the samples. To evaluate the potential immunogenic response of the peptide-derivatized constructs, a real-time polymerase chain reaction (RT-PCR) system that allows for the in vitro analysis and quantification of the cellular inflammatory responses tumor necrosis factor alpha (TNF-alpha) and interleukin-1 beta (IL1-beta) was utilized. The inflammatory response to the peptide-functionalized SCK nanoparticles as measured by RT-PCR show statistically significant increases in the levels of both TNF-alpha and IL1-beta relative to tissue culture polystyrene (TCPS). However, the measured cytokine levels did not preclude the further testing of SCKs in an in vivo mouse immunization protocol. In this limited assay, measured increases in immunoglobulin G (IgG) concentration in the sera were minimal with no specific interactions being isolated, and more importantly, none of the mice (>50) subjected to the three 100 microg immunization protocol have died. Additionally, no gross morphological changes were observed in postmortem organ histology examinations.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Bioconjugate chemistry

DOI

EISSN

1520-4812

ISSN

1043-1802

Publication Date

July 2004

Volume

15

Issue

4

Start / End Page

710 / 717

Related Subject Headings

  • Tumor Necrosis Factor-alpha
  • Peptides
  • Organic Chemistry
  • Nanotechnology
  • Nanostructures
  • Mice
  • Interleukin-1
  • Inflammation
  • Gene Products, tat
  • Flow Cytometry
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Becker, M. L., Bailey, L. O., & Wooley, K. L. (2004). Peptide-derivatized shell-cross-linked nanoparticles. 2. Biocompatibility evaluation. Bioconjugate Chemistry, 15(4), 710–717. https://doi.org/10.1021/bc049945m
Becker, Matthew L., LeeAnn O. Bailey, and Karen L. Wooley. “Peptide-derivatized shell-cross-linked nanoparticles. 2. Biocompatibility evaluation.Bioconjugate Chemistry 15, no. 4 (July 2004): 710–17. https://doi.org/10.1021/bc049945m.
Becker ML, Bailey LO, Wooley KL. Peptide-derivatized shell-cross-linked nanoparticles. 2. Biocompatibility evaluation. Bioconjugate chemistry. 2004 Jul;15(4):710–7.
Becker, Matthew L., et al. “Peptide-derivatized shell-cross-linked nanoparticles. 2. Biocompatibility evaluation.Bioconjugate Chemistry, vol. 15, no. 4, July 2004, pp. 710–17. Epmc, doi:10.1021/bc049945m.
Becker ML, Bailey LO, Wooley KL. Peptide-derivatized shell-cross-linked nanoparticles. 2. Biocompatibility evaluation. Bioconjugate chemistry. 2004 Jul;15(4):710–717.
Journal cover image

Published In

Bioconjugate chemistry

DOI

EISSN

1520-4812

ISSN

1043-1802

Publication Date

July 2004

Volume

15

Issue

4

Start / End Page

710 / 717

Related Subject Headings

  • Tumor Necrosis Factor-alpha
  • Peptides
  • Organic Chemistry
  • Nanotechnology
  • Nanostructures
  • Mice
  • Interleukin-1
  • Inflammation
  • Gene Products, tat
  • Flow Cytometry